A comprehensive motifs-based interactome of the C/EBPα transcription factor by Ramberger, E. et al.
A comprehensive motifs-based interactome of the C/EBPα 1 
transcription factor 2 
 3 
Ramberger, Evelyn1, Sapozhnikova, Valeria1, Kowenz-Leutz, Elisabeth1, 4 
Zimmermann, Karin1, Nicot, Nathalie2, Nazarov, Petr V.2, Perez-Hernandez, Daniel1,2, 5 
Reimer, Ulf3,  Mertins, Philipp1, Dittmar, Gunnar1,2, Leutz, Achim1,4,* 6 
1 Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Robert-7 
Rössle-Strasse 10, 13125 Berlin, Germany 8 
2 Quantitative Biology Unit, Luxembourg Institute of Health, Luxembourg 9 
3JPT Peptide Technologies GmbH, Volmerstrasse 5, 12489 Berlin, Germany 10 
4 Institute of Biology, Humboldt University of Berlin, 10115 Berlin, Germany 11 
 12 
*Corresponding author: aleutz@mdc-berlin.de 13 
 14 
Keywords: intrinsic disorder, CEBPA interactome, BioID, peptide array, mass-15 
spectrometry 16 
  17 
.CC-BY-ND 4.0 International licenseperpetuity. It is made available under a
preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in 
The copyright holder for thisthis version posted December 28, 2020. ; https://doi.org/10.1101/2020.12.28.424569doi: bioRxiv preprint 
Abstract  18 
The pioneering transcription factor C/EBPα coordinates cell fate and cell 19 
differentiation. C/EBPα represents an intrinsically disordered protein with multiple 20 
short linear motifs and extensive post-translational side chain modifications (PTM), 21 
reflecting its modularity and functional plasticity. Here, we combined arrayed peptide 22 
matrix screening (PRISMA) with biotin ligase proximity labeling proteomics (BioID) to 23 
generate a linear, isoform specific and PTM-dependent protein interaction map of 24 
C/EBPα in myeloid cells. The C/EBPα interactome comprises promiscuous and PTM-25 
regulated interactions with protein machineries involved in gene expression, 26 
epigenetics, genome organization, DNA replication, RNA processing, and nuclear 27 
transport as the basis of functional C/EBPα plasticity. Protein interaction hotspots 28 
were identified that coincide with homologous conserved regions of the C/EBP family 29 
and revealed interaction motifs that score as molecular recognition features (MoRF). 30 
PTMs alter the interaction spectrum of multi-valent C/EBP-motifs to configure a 31 
multimodal transcription factor hub that allows interaction with multiple co-regulatory 32 
components, including BAF/SWI-SNF or Mediator complexes. Combining PRISMA 33 
and BioID acts as a powerful strategy to systematically explore the interactomes of 34 
intrinsically disordered proteins and their PTM-regulated, multimodal capacity.  35 
  36 
.CC-BY-ND 4.0 International licenseperpetuity. It is made available under a
preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in 
The copyright holder for thisthis version posted December 28, 2020. ; https://doi.org/10.1101/2020.12.28.424569doi: bioRxiv preprint 
Key points 37 
• Integration of proximity labeling and arrayed peptide screen proteomics refines 38 
the interactome of C/EBPα isoforms 39 
• Hotspots of protein interactions in C/EBPα mostly occur in conserved short linear 40 
motifs  41 
• Interactions of the BAF/SWI-SNF complex with C/EBPα are modulated by 42 
arginine methylation and isoform status 43 
• The integrated experimental strategy suits systematic interactome studies of 44 
intrinsically disordered proteins  45 
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Introduction 46 
CCAAT enhancer binding protein alpha (C/EBPα) is a lineage instructing pioneering 47 
transcription factor involved in cell fate decisions in various cell types, including 48 
myeloid cells, adipocytes, hepatocytes, and skin cells. In myelopoiesis, C/EBPα 49 
cooperates with other transcription factors and chromatin modifying enzymes to 50 
regulate hematopoietic stem cell biology, lineage choice and expression of myeloid 51 
genes (Avellino and Delwel, 2017; Zaret and Carroll, 2011). Knockout experiments in 52 
mice show that C/EBPα regulates hematopoietic stem cell functions and that its 53 
removal blocks progenitor differentiation at the myeloid commitment stage 54 
(Bereshchenko et al., 2009; Kirstetter et al., 2008a; Zhang et al., 2004). The 55 
intronless CEBPA gene is mutated in approximately 10-15% of human acute myeloid 56 
leukemia (AML) cases. Mutations located within the N-terminal part of the gene 57 
obstruct expression of the full-length isoform p42 C/EBPα and favor expression of 58 
the N-terminally truncated isoform p30 C/EBPα (Fasan et al., 2014; Lin et al., 2005; 59 
Pabst et al., 2001). Experimental hematology and targeted mouse genetics have 60 
demonstrated that p30 C/EBPα represents a highly penetrant AML gene 61 
(Bereshchenko et al., 2009; Kirstetter et al., 2008b).  62 
Unraveling the protein interaction network of C/EBPα in hematopoietic cells is a 63 
prerequisite for the understanding of diverse gene regulatory and epigenetic 64 
functions of C/EBPα in normal hematopoiesis and AML. Previous research has 65 
shown that the N-terminus of vertebrate C/EBPα harbors short, conserved regions 66 
(CRs) that function in a modular and combinatorial fashion to regulate gene 67 
expression (Leutz et al., 2011; Tsukada et al., 2011). The N-terminally truncated, 68 
leukemogenic p30 C/EBPα isoform contains only one of the transactivation modules 69 
(CR1L, TEIII). P30 C/EBPα retains residual gene regulatory and epigenetic capacity 70 
to direct myeloid lineage commitment but lacks the cell maturation inducing and 71 
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proliferation restricting functions of the long C/EBPα isoform p42 (Bereshchenko et 72 
al., 2009; Pedersen et al., 2001). Only the C-terminal part of C/EBPα, comprising 73 
approximately one quarter of the protein, may adopt a structured basic leucine zipper 74 
(bZIP) domain upon binding to DNA target sites (Seldeen et al., 2008). Otherwise, 75 
C/EBPα and other family members represent mosaics of intrinsically disordered 76 
regions (IDRs) with alternating small linear motifs (SLiM) and molecular recognition 77 
features (MoRF), typical hallmarks of gene regulatory proteins that integrate signal 78 
transmission, gene regulation, and epigenetic regulation through promiscuous 79 
interactomes (Dunker et al., 2002; Dyson and Wright, 2005; Tompa, 2012; Uversky 80 
et al., 2005; van der Lee et al., 2014; Ward et al., 2004; Wright and Dyson, 1999). 81 
PTMs, downstream of signaling cascades, frequently alter dynamic protein 82 
interaction interfaces of IDR/SLiM/MoRF modules and are of high biological 83 
relevance but remain difficult to capture with traditional immune affinity-based 84 
methods as a result of their transient nature, weak affinity, and/or sub-stoichiometric 85 
participation in biomolecular condensates (Perkins et al., 2010; Sabari et al., 2020). 86 
Within the C/EBP family, mutation of PTM sites, including phosphorylation (S, T, Y 87 
residues), methylation (K, R residues), and acetylation sites (K residues) or deletion 88 
of CRs in their N-termini may radically alter their biological functions (Leutz et al., 89 
2011).  90 
Assessment of the known C/EBPα interactome data showed a surprisingly low 91 
overlap (less than 5%) between various published immuno-affinity-mass 92 
spectrometry (MS) datasets, hampering the deduction of C/EBPα functions and 93 
adjunct molecular mechanisms (Cirilli et al., 2017; Giambruno et al., 2013; Grebien et 94 
al., 2016). Here, we combined the protein interaction screen using a peptide matrix 95 
(PRISMA) method (Dittmar et al., 2019) with biotin proximity labeling identification 96 
(BioID) (Roux et al., 2012) to match high confidence interactomes across the primary 97 
sequence and PTM sites with the p42/p30 C/EBPα isoforms in living myeloblastic 98 
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cells. This experimental strategy may be adapted to explore other multi-valent 99 
intrinsically disordered transcriptional regulators, many of which are involved in 100 
development and disease. 101 
 102 
Results 103 
Mapping the C/EBPα interactome with PRISMA 104 
We have previously established the PRISMA method to explore the linear 105 
interactomes of intrinsically disordered proteins and applied it to C/EBPβ and its 106 
PTMs (Dittmar et al., 2019). Here, we slightly modified the PRISMA protocol to 107 
explore the linear and PTM-dependent C/EBPα interactome. Briefly, membrane spot-108 
synthesized, tiling peptides that covered the primary sequence of C/EBPα were 109 
incubated with nuclear extracts derived from the human promyelocytic leukemia cell 110 
line, NB4. Bound proteins of each spot were subsequently analyzed using 111 
quantitative mass spectrometry (Figure 1A). The C/EBPα peptide array included 114 112 
peptides with and without PTMs that were designed with a sequence overlap of 113 
seven amino acids (Supplemental Table 1). PTMs within the bZIP domain were 114 
omitted from the PRISMA screen since they may modulate DNA binding in addition 115 
to protein interactions. The overall technical reproducibility of the PRISMA screen 116 
replicates showed a median Pearson correlation coefficient of 0.85 and discrete 117 
patterns of correlation between different C/EBPα regions (Supplemental Figure 1). 118 
PRISMA detected a total of 2,274 proteins, of which 785 proteins passed the 119 
significance threshold (FDR < 0.1) in at least one peptide spot (Supplemental Table 120 
2). The majority of significant protein interactions were observed in the regions CR2, 121 
CR3, CR4 and CR1L, which together correspond to the trans-regulatory regions of 122 
C/EBPα (Leutz et al., 2011). Extracted binding profiles, as shown in Figure 2C, 123 
.CC-BY-ND 4.0 International licenseperpetuity. It is made available under a
preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in 
The copyright holder for thisthis version posted December 28, 2020. ; https://doi.org/10.1101/2020.12.28.424569doi: bioRxiv preprint 
highlight distinct interaction profiles of selected protein complexes such as Mediator, 124 
or BAF/SWI-SNF components, previously shown to interact with C/EBPα. 125 
The mediator of transcription complex (MED) is an essential transcriptional 126 
coactivator in eukaryotes that interacts with RNA Pol II and many transcription factors 127 
and co-factors. PRISMA revealed 17 MED proteins with similar binding patterns with 128 
dominant peaks in C/EBPα peptides corresponding to CR2,3,4 and CR1L. This 129 
finding suggests that the MED-complex interacts with multiple CRs in the N-terminus 130 
of p42 C/EBPα and with CR1L/TEIII, which corresponds to the N-terminus of p30 131 
C/EBPα. The acetyltransferases, CBP/p300 (KAT3A/KAT3B), most strongly bound to 132 
peptides spanning regions CR3,4 with residual binding in CR2 and CR1L. Interaction 133 
with the chromatin remodeling BAF/SWI-SNF complex is essential for the anti-134 
proliferative and differentiation functions of C/EBPα and has been previously found to 135 
require CR1L/TEIII in addition to the N-terminus of p42 C/EBPα (Muller et al., 2004; 136 
Pedersen et al., 2001). In PRISMA, BAF/SWI-SNF subunits bound to peptides 137 
corresponding to CR1L and CR3,4.  138 
C/EBP proteins are extensively decorated with PTMs that may alter their interactome 139 
to direct their function (Kowenz-Leutz et al., 2010; Leutz et al., 2011). Of particular 140 
interest are a number of C/EBP-family member specific arginine residues, several of 141 
which have been shown in C/EBPβ to be targets of mono- and di-methylation, with 142 
their mutation profoundly changing C/EBPβ biology (Dittmar et al., 2019; Leutz et al., 143 
2011). We examined C/EBPα for PTMs by mass spectrometry and discovered 144 
several known and novel methylation sites, including methylation of R12, R35 and 145 
R156 and further identified R142 (CR1L) by a targeted MS-parallel reaction 146 
monitoring approach as a novel methylation site (Supplemental Table 3 and 147 
Supplemental Figure 2). The PRISMA data suggested increased binding of the 148 
BAF/SWI-SNF subunit SMARCE1 to R142 methylated peptides, as compared to the 149 
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unmodified counterpart. Other subunits of BAF/SWI-SNF (SMARCA4, SMARCC2) 150 
followed a similar trend but their differential binding to the methylated peptide 151 
spanning R142 scored somewhat below the threshold set of statistical significance. 152 
Given the sequence conservation between CEBP proteins, we compared the 153 
PRISMA derived interactome of C/EBPα with the previously published C/EBPβ 154 
PRISMA interactome (Dittmar et al., 2019). Despite some sequence differences in 155 
homologous regions and peptides, several shared interactors were identified. For 156 
example, the mediator complex was found to bind to the same homologue CRs in 157 
both proteins (Supplemental Figure 3), confirming the functional similarity of these 158 
regions within the CEBP family (Jones et al., 2002).  159 
 160 
Cross-validation of PRISMA and BioID-C/EBPα interactomes 161 
Next, we compared the interactomes derived from PRISMA and BioID proximity 162 
labeling data to generate a myeloid live cell validated linear C/EBPα interactome 163 
(Figure 2 A). Briefly, NB4 cells were transduced with a Tet-On inducible lentiviral 164 
construct encoding a promiscuous biotin ligase (BirA*) fused to the C-terminus of 165 
C/EBPα. As controls, we used non-induced NB4 C/EBPα-BirA* cells or cells 166 
expressing only the ligase moiety (NB4 BirA*). Proximity labeling identified 397 167 
C/EBPα proximal interactors (FDR < 0.05). Among the most enriched proteins were 168 
several transcription factors of the C/EBP and ATF families, representing known 169 
heterodimerization partners of C/EBPα (Tsukada et al., 2011) and thus confirming 170 
successful BioID labeling (Figure 2B, Supplemental Table 4).  171 
In total, 88 proteins overlapped between the PRISMA and BioID derived C/EBPα 172 
interactomes of which 21 were previously identified interactors, including members of 173 
chromatin remodeling and histone acetylation / deacetylation complexes. In addition, 174 
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49 proteins significant in PRISMA and 26 proteins significant in BioID have been 175 
previously described to interact with C/EBPα (Chatr-Aryamontri et al., 2017; Grebien 176 
et al., 2016; Szklarczyk et al., 2015). Taken together, 137 proteins represent the 177 
subset of myeloid C/EBPα interactors with the highest confidence that can be 178 
depicted across the linear C/EBPα sequence +/- PTM sites. These interactors show 179 
high connectivity according to experimentally validated interactions listed in the 180 
STRING database (Figure 2C). Using the spatial information provided by PRISMA, 181 
we could also reveal distinct functional roles of individual CRs including chromatin 182 
remodeling (CR3,4; CR1L; bZIP), transcriptional regulation (CR2; CR3,4; CR1L; 183 
CR6; bZIP) and hematopoietic progenitor cell differentiation (CR3,4) (Supplemental 184 
Figure 4). CR3,4 is of particular interest since it contains most of the significantly 185 
enriched GO terms, confirming the importance of the core transactivating region of 186 
p42 C/EBPα. Although several proteins interacted with CR7, no GO terms were 187 
enriched with this region, pointing towards functional heterogeneity.  188 
 189 
Arginine methylation-dependent interaction of BAF/SWI-SNF complex subunits 190 
Differential interactions with post-translationally modified peptides in the primary 191 
C/EBPα sequence were also detected by PRISMA. Among them was the BAF/SWI-192 
SNF complex that has been previously described to interact with C/EBPα (Pedersen 193 
et al., 2001). PRISMA revealed that the interaction with the SMARCE1 component is 194 
modulated by the newly discovered arginine methylation site R142 within CR1L/TEIII 195 
(Figure 3A). Accordingly, we performed BioID with a R142/149/156 to L142/149/156 196 
mutant (triple R to L mutation; tR>L) of C/EBPα to examine the PTM-dependent 197 
BAF/SWI-SNF interaction in more detail. In accordance with the PRISMA results, 198 
SMARCE1 and three additional BAF/SWI-SNF subunits (ARID1A, ARID1B, ARID2) 199 
were significantly enriched in the p30 C/EBPα-tR>L mutant, as compared to the WT 200 
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p30 C/EBPα-BioID (Figure 3B). BioID with p30 C/EBPα-tR>L also verified the 201 
methylation-dependent interaction with the E3 ubiquitin ligase TRIM33 and the NuRD 202 
complex component GATAD2A, as also detected by PRISMA. In addition, several 203 
Myb-Muvb/DREAM complex members (LIN9, LIN37, MYBL2) were identified as p30 204 
C/EBPα-tR>L-specific interactors but were not detected in PRISMA.  205 
 206 
C/EBPα isoform specific interactions detected with BioID 207 
The PRISMA data predicted that p30 C/EBPα isoform can still function to recruit 208 
major components of the transcriptional and epigenetic machinery, albeit with lower 209 
efficiency compared to p42 C/EBPα. To further examine the differences between the 210 
two C/EBPα isoforms, we expressed p42 and p30 C/EBPα as BioID fusions in NB4 211 
cells to compare their BioID interactomes. The isoform-specific interactomes (Figure 212 
4A, Supplemental Table 4) confirmed the binding profiles observed in PRISMA: p42 213 
specific interactors bound more strongly to PRISMA peptides corresponding to the N-214 
terminal, p42 unique part of C/EBPα, while p30 specific interactors predominantly 215 
bound to PRISMA peptides corresponding to C-terminal C/EBPα regions (Figure 216 
4B). In accordance with the PRISMA interactions, most interactors identified by in 217 
vivo proximity labelling were found to interact with both C/EBPα isoforms (Figure 218 
4C). These data suggest that multi-valent interactions with different affinities may 219 
occur with distinct C/EBPα CRs, including CR1L as part of p30 C/EBPα. Overall, p42 220 
C/EBPα-BioID and p30 C/EBPα-BioID pulldowns revealed 71 and 9 interactors that 221 
preferentially interacted with p42 and p30 C/EBPα, respectively.  222 
Proteins differentially interacting with the p30 C/EBPα isoform and its PTMs may 223 
pose a selective vulnerability for AML cells expressing p30 C/EBPα. We therefore 224 
extracted CRISPR Cas9 knockout study derived dependency scores of the nine p30 225 
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C/EBPα specific interactors in 18 different AML cell lines using the DepMap Portal 226 
(Supplemental Figure 5) (Tsherniak et al., 2017). Among the AML cell lines 227 
inspected, 9 out of 18 scored as sensitive to TFAP4 knockout (threshold < – 0.5). 228 
Two and one cell line tested were sensitive to GATA1 and BCL11A or BLM knockout, 229 
respectively. The p30 C/EBPα specific binding of the BAF/SWI-SNF complex 230 
member BCL11A further highlights context-specific regulation of BAF/SWI-SNF 231 
complex interaction to C/EBPα isoforms. 232 
To analyze connections between the C/EBPα isoform specific interactome with the 233 
transcriptome we also performed RNA expression analysis of NB4 cell lines 234 
ectopically expressing p42 or p30 C/EBPα. We found that despite the largely 235 
overlapping interactome, the two isoforms induced differential gene expression 236 
changes (Figure 4D) that could be attributed to differential interactions with other 237 
transcription factors. Gene expression profiles were analyzed using gene set 238 
enrichment analysis (GSEA) employing immunologic and transcription factor target 239 
databases from the molecular signature database (Subramanian et al., 2005) (Figure 240 
4E). The erythroid transcription factor GATA1 was found to interact differentially with 241 
p30 C/EBPα; GSEA analysis detected enrichment of a GATA1 signature specifically 242 
in p30 C/EBPα expressing cells. Likewise, PPARG specifically interacts with p42 243 
C/EBPα and p42 expressing cells also displayed significant enrichment of a 244 
previously published macrophage PPARG gene signature (Roszer et al., 2011). Data 245 
from BioID experiments indicated that EGR1 specifically interacted with p42 C/EBPα. 246 
Interestingly, we found that a gene signature based on the presence of EGR1 motifs 247 
was enriched in p30 but not p42 C/EBPα expressing cells. RNA expression levels of 248 
EGR1 were upregulated by both p42 and p30 expression. Indirect interaction of 249 
EGR1 with DNA not at EGR1 motifs, but through other CEBPs, has been described 250 
previously (Jakobsen et al., 2013) and may contribute to the differential EGR1 251 
signature observed. Taken together, our data suggest that the specific interactions of 252 
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C/EBPα isoforms with lineage defining transcription factors are implicated in co-253 
regulation of target genes in the hematopoietic system.  254 
 255 
Discussion 256 
In the present study, we combined peptide array screening and BioID to fine map the 257 
interactome of the intrinsically disordered transcription factor C/EBPα. The 258 
integration of both methods overcame limitations of classical immuno-affinity based 259 
interactomes of intrinsically disordered proteins. Contribution of individual PTMs and 260 
protein regions to the interactome remain difficult to deconvolute in classical pull-261 
down MS approaches, while PRISMA reveals both SLiM- and PTM-dependent 262 
interactions (Dittmar et al., 2019; Meyer and Selbach, 2020). Moreover, transient 263 
interactions mediated by IDRs/SLiMs are easily lost during affinity-purification. In 264 
contrast, BioID covalently biotinylates proteins that engage with C/EBPα in the living 265 
cell and thus enables the detection of transient and dynamic interactions (Roux et al., 266 
2012). Altogether, PRISMA and BioID revealed 785 and 397 interacting proteins, 267 
respectively, and the overlay of C/EBPα BioID and PRISMA data sets with public 268 
resources disclosed a linear, high confidence C/EBPα core-interactome of 137 269 
proteins. The C/EBPα core-interactome can be depicted as an interaction landscape 270 
across the C/EBPα sequence and PTM sites and its components were found to be 271 
highly interconnected. In addition to known C/EBPα interactors that operationally 272 
represent positive controls, we also discovered novel associations of C/EBPα with 273 
proteins involved in gene expression and epigenetic regulation, chromosome 274 
organization, RNA processing, and DNA replication, extending the repertoire of 275 
myeloid C/EBPα targets and associated functions. The majority of C/EBPα 276 
interactions were nevertheless detected in only one of the two datasets. Some of the 277 
unique C/EBPα interactors detected by BioID may require more complex, 278 
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simultaneously occurring, multi-site interactions or multiple induced fit processes and 279 
were missed in PRISMA. Discrepancies may also relate to restriction of BioID to 280 
proximal interactions, the absence of suitable biotinylation sites, or stability during the 281 
labelling period. PRISMA, on the other hand, may readily detect distal, secondary 282 
interactors, such as in large protein complexes. 283 
PRISMA revealed major hotspots of SLiM-based protein interactions in C/EBPα that 284 
strongly correlated with data derived from the related transcription factor C/EBPβ 285 
(Dittmar et al., 2019; Leutz et al., 2011). The interactors shared between C/EBPα 286 
and C/EBPβ may help to explain the partially redundant functions of both proteins 287 
(Chen et al., 2000; Hirai et al., 2006; Jones et al., 2002). Many of the co-regulators 288 
identified also displayed multiple interactions with several SLiMs/MoRFs/CRs, 289 
predominantly in CR2,3,4 and CR1L. These regions correspond to previously defined 290 
trans-regulatory regions found within the C/EBP family (Leutz et al., 2011). The same 291 
conserved regions scored highly as molecular recognition features (MoRF; Figure 292 
1B) that may undergo induced folding and transient disorder-to-order transition 293 
during contact with partner proteins (Oldfield et al., 2005). For example, the region 294 
CR3,4 of C/EBPε was previously shown to fold into two short orthogonal amphipathic 295 
helical regions on interaction with the TAZ2 domain of CBP (Bhaumik et al., 2014). 296 
Likewise, CBP/p300 was found to interact with PRISMA peptides covering CR3,4 of 297 
C/EBPα, in concordance with homologous regions in C/EBPβ (Dittmar et al., 2019). 298 
Interestingly, CR3,4 in C/EBPα and C/EBPε are separated by only few amino acids, 299 
whereas species-specific IDRs separate both CRs in C/EBPβ, suggesting structural 300 
spatial flexibility and independent, yet combinatorial functions of CR3,4.  301 
Many regulatory proteins involved in signaling, gene expression, and epigenetics 302 
harbor IDRs and PTMs that determine their function and connectivity (Dyson and 303 
Wright, 2005, 2016). Although protein interactions directed by SLiMs are in general of 304 
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low affinity, they may nevertheless exhibit high specificity. This raises the question of 305 
how specificity is achieved. Specificity may be forged by the combined action of 306 
several SLiMs and PTMs to regulate selective interactions of a subset of SLiMs at a 307 
time. Multivalent, promiscuous interactions of transcription factors with co-regulatory 308 
proteins have been observed before and may relate to context dependent contacts 309 
during dynamic gene regulatory processes (Brzovic et al., 2011; Clark et al., 2018; 310 
Vojnic et al., 2011). IDRs within and between SLiMs permit structural flexibility and 311 
dynamic interactions, which can also drive the formation of specific protein 312 
condensates with transiently favorable interactions (Hahn, 2018). This concept is in 313 
accordance with the promiscuous nature of SLiMs and may reflect dynamic multi-314 
modal regulation with the rapid exchange of alternative interaction partners (Dyson 315 
and Wright, 2016; Ivarsson and Jemth, 2019). Modular transactivation domains in 316 
conjunction with multi-valency are thought to participate in or to initiate biomolecular 317 
condensates that involve dynamic, “fuzzy” interactions with multiple co-regulators in 318 
interaction hubs (Boija et al., 2018; Brzovic et al., 2011; Chong et al., 2018; Hahn, 319 
2018; Martin and Holehouse, 2020; Tuttle et al., 2018). Remarkably, the C/EBPα 320 
primary sequence shows a very high degree of “fuzziness” with strong predictions as 321 
initiator regions of liquid-liquid phase separation in the N-terminus (Figure 1B, red 322 
line), while the PRISMA interaction hotspots largely coincide within regions that show 323 
maxima of MoRF predictions (Figure 1B, blue line) (Horvath et al., 2020; Malhis et 324 
al., 2016). 325 
Our data show that PTMs in C/EBPα may orchestrate multi-modal functions of 326 
C/EBPα by modulating interactions with the components of transcriptional and 327 
epigenetic machinery. The comparison of C/EBPα WT and the R142L methylation 328 
mimicry mutant by proximity labeling confirmed the differential interaction with 329 
BAF/SWI-SNF components, as detected by PRISMA. These data are consistent with 330 
previous findings showing that BAF/SWI-SNF interacts with CR1L (Muller et al., 331 
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2004; Pedersen et al., 2001). The newly discovered R142 methylation-dependent 332 
differential interaction of BAF/SWI-SNF will help to conceive hypothesis driven 333 
approaches to explore arginine methyltransferase-dependent epigenetic downstream 334 
events. 335 
Data presented here further demonstrate that most of the C/EBPα interactors bind to 336 
both C/EBPα isoforms, whereas a subset of 71 and 9 proteins preferentially 337 
interacted with the p42 and p30 C/EBPα isoform, respectively. Many of the shared 338 
C/EBPα interactors showed diminished signal strength in p30 C/EBPα BioID, 339 
supporting the concept of p30 as a “weak” C/EBPα variant with relatively few 340 
exclusive binding partners. This view is supported by the fact that defective 341 
myelopoiesis in the absence of C/EBPα was largely rescued by p30 C/EBPα, 342 
although p30, in the absence of p42 C/EBPα, eventually elicits AML (Bereshchenko 343 
et al., 2009; Kirstetter et al., 2008). Interestingly, several of the p30 C/EBPα-specific 344 
binders (TFAP4, GATA1, BCL11A) affect the survival of AML cell lines. The p30 345 
C/EBPα specific interaction with GATA1 may further hint at a role at the branch point 346 
of erythroid / myeloid commitment in replicative multi-potential progenitors (Drissen et 347 
al., 2019), whereas p42 C/EBPα specific interactors, such as EGR1 or PPARγ, are 348 
important regulators of myeloid differentiation (Chinetti et al., 1998; Krishnaraju et al., 349 
2001; Lefterova et al., 2010; Lefterova et al., 2008; Mildner et al., 2017; Nguyen et 350 
al., 1993; Roszer et al., 2011; Tontonoz et al., 1994).  351 
In summary, the cross-validated myeloid C/EBPα interaction map presented in this 352 
study may serve as a resource for further exploration of the biological importance of 353 
individual and combinatorial SLiM and PTM functions of C/EBPα. Beyond the 354 
C/EBPα,β interactomes, the integration of PRISMA and BioID approaches may help 355 
to explore the linear and PTM dependent interactomes of many other important 356 
intrinsically disordered proteins involved in cell signaling and cell fate determination. 357 
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Materials and Methods 358 
Cell culture 359 
NB4 cells were acquired from Leibniz Institute DSMZ- German Collection of 360 
Microorganisms and Cell Culture, Germany (DSMZ no.: ACC 207). Cells were 361 
cultivated in a humidified incubator at 37°C, 5% CO2 in RPMI1640. For metabolic 362 
labeling, NB4 cells were grown in SILAC RPMI1640 supplemented with 10% dialyzed 363 
FCS, 100 mg/ml penicillin-streptomycin, 25mM HEPES, 28 µg/ml L-arginine and 364 
48.67 µg/ml L-lysine (light) 13C615N2 (heavy lysine) or L-lysine D4 (medium heavy 365 
lysine).  366 
 367 
Plasmids and Generation of Cell Lines 368 
The rat C/EBPα p30 3L mutant (R140; 147; 154 mutated to leucine) was generated 369 
using the QuickChange Site Directed Mutagenesis Kit according to the 370 
manufacturer’s protocol (Agilent #200519). The BirA Ligase containing plasmid was 371 
purchased (Addgene #64395). The BirA Ligase was cloned in frame to the C/EBPα 372 
C-terminus using BamHI and XhoI restriction sites. PCR primer: 5’- 373 
CGCGGATCCAGCGGTGGAAGTGGTGGCCTGAAGGACAACACCGTG and 3’- 374 
TGCTCTAGACTCGAGTTATTTATCGTC. The C/EBPα p42, p30 or p30 R3L-BirA 375 
Ligase fragments were cloned into the pENTRY2B vector (Clontech #3064) using 376 
BamHI and XhoI restriction sites and subsequently introduced into the pInducer21 377 
GFP lentiviral vector (Clontech #3044) using the Gateway LR Clonase TM II cloning 378 
kit (ThermoFisher Scientific #11791-020). Viral supernatants were obtained from 379 
Lenti-X 293T cells (Clontech #632180) transfected with either pInducer21 GFP 380 
lentiviral vector or pInducer21 GFP constructs containing either p42, p30 WT-BirA 381 
Ligase, p30 R3L-BirA Ligase, or pInducer21 GFP-BirA ligase only using Lenti-X 382 
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Packing Single Shots (Clontech #631275) according to the manufacturer’s protocol. 383 
NB4 cells were centrifuged (1 h, 900g) with infectious supernatant collected 72 h 384 
after transfection and 8 µg/mL hexadimethrine bromide and left for recovery 385 
overnight. GFP positive NB4 cells were sorted twice using an Aria II sorter (Becton 386 
Dickinson) three days after infection. 387 
 388 
NB4 induction  389 
NB4 cells were briefly treated with differentiation inducing agents prior to harvesting. 390 
SILAC labeled NB4 cells were seeded during exponential growth in SILAC media 391 
supplemented with 2µM all-trans-retinoic acid (ATRA; heavy), 50nM 392 
Tetradecanoylphorbol-acetat (TPA; medium heavy) or solvent only (light). Cells were 393 
harvested after 12h (ATRA and solvent only treated cells) or 6h (TPA treated cells) 394 
and nuclear extracts were prepared as described.  395 
Nuclear extract preparation 396 
Nuclear extracts from NB4 cells were prepared as described previously (Dignam et 397 
al., 1983) with slight modifications. NB4 cells were harvested by centrifugation at 398 
1000g, 4 min at 4°C and washed twice with ice cold PBS. Packed cell volume (pcv) 399 
was estimated and cells were resuspended in 5xpcv of ice-cold hypotonic buffer 400 
(10mM HEPES pH 7.5, 10mM NaCl, 3mM MgCl2) supplemented with protease 401 
inhibitors. Cells were incubated on ice for 5 min, followed by addition of dodecyl-β-D-402 
maltosid (DDM) to a final concentration of 0.05%. The sample was vortexed briefly 403 
and immediately centrifuged for 5 min at 600g, 4°C. The cytosolic fraction was 404 
removed and the nuclei were washed with 20xpcv hypotonic buffer (5 min, 600g, 405 
4°C). The supernatant was removed and the nuclei were washed with 20xpcv PBS (5 406 
min, 600g, 4°C). The nuclei were extracted with 2/3xpcv of high salt buffer (20mM 407 
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HEPES pH 7.5, 400mM NaCl, 1mM EDTA ph 8, 1mM EGTA pH 8, 20% glycerol, 408 
1mM DTT) supplemented with protease inhibitors while shaking on a tubeshaker at 409 
4°C for 20 min at 750 rpm. Nuclear extracts were cleared by centrifugation at 18000g 410 
for 20 min at 4°C and the buffer was exchanged to membrane binding buffer (20mM 411 
HEPES pH 7.5, 400mM NaCl, 1mM EDTA ph 8, 1mM EGTA pH 8, 25% glycerol, 412 
1mM DTT) by gel filtration with PD MidiTrap G10 columns (GE healthcare) according 413 
to instructions of manufacturers.  414 
 415 
Protein Interaction Screen on a peptide Matrix 416 
Custom PepSpot cellulose membranes were ordered from JPT and PRISMA was 417 
performed as described before (Dittmar et al., 2019) with slight adaptations. All 418 
washing and incubation steps were performed at 4°C on a rocking platform set to 419 
700 rpm. Membranes were wetted in membrane binding buffer for 15 min, followed 420 
by a blocking step with 1 mg/ml yeast tRNA in membrane binding buffer for 10 min. 421 
Membranes were washed 5 x for 5 min with membrane binding buffer and incubated 422 
with nuclear extracts on ice for 30 min. The protein extract was removed and the 423 
membranes were washed 3 x 5 min with membrane binding buffer. The individual 424 
peptide spots were punched out with a 2mm biopsy puncher and placed into single 425 
wells of a 96 well plate containing 20µl denaturation buffer (6M urea, 2M thiourea, 426 
10mM HEPES pH 8). The samples were digested in solution on a PAL robot system. 427 
In brief, proteins were reduced with 1mM TCEP for 30 min followed by alkylation with 428 
5mM CAA for 20 min. To each sample 0.5 µg of sequencing grade lysyl 429 
endopeptidase (LysC) was added. Samples were digested for 2h before being diluted 430 
with four volumes of 50mM ammonium-bi-carbonate and continuation of the digestion 431 
over night at room temperature. Digested samples were acidified with TFA and 432 
desalted with C18 stage tips as described before (Rappsilber et al., 2003). 433 
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LC MS/MS 434 
Desalted and dried peptides were resuspended in MS sample buffer (3% ACN/ 0.1% 435 
FA) and separated online with a Easy-nLCTM 1200 coupled to a Q-exactive+ or a Q 436 
exactive HF-X mass spectrometer equipped with an orbitrap electrospray ion source. 437 
Samples were separated on line on a 20 cm reverse-phase column (inner diameter 438 
75µm) packed in house with 3 µm C18-Reprosil beads with a linear gradient ramping 439 
from 3% to 76% acetonitrile. PRISMA samples were separated with a 1h gradient 440 
and MS data was acquired on a Q-exactive+ in data dependent acquisition mode 441 
with a top10 method. Full scan MS spectra were acquired at a resolution of 70 000 in 442 
the scan range from 300 to 1700 m/z, automated gain control (AGC) target value of 443 
1e6 and maximum injection time of 120ms. MS/MS spectra were acquired at a 444 
resolution of 17500, AGC target of 1e5 and maximum IT of 60 ms. Ions were isolated 445 
with a 2 m/z isolation window and normalized collision energy was set to 26. 446 
Unassigned charge states and single charged precursors were excluded from 447 
fragmentation and dynamic exclusion was set to 20s. BioID pulldowns were 448 
separated on with a 2h gradient and MS data was acquired on a Q-exactive HF-X in 449 
data dependent acquisition mode with a top20 method. Full scan MS spectra were 450 
acquired at a resolution of 60000 in the scan range from 350 to 1700 m/z, automated 451 
gain control (AGC) target value was set to 3e6 and maximum injection time to 10ms. 452 
MS/MS spectra were acquired at a resolution of 30000, AGC target of 1e5 and 453 
maximum IT of 86 ms. Ions were isolated with a 1.6 m/z isolation window and 454 
normalized collision energy was set to 26. Unassigned charge states and ions with a 455 
chare state of one, seven or higher were excluded from fragmentation and dynamic 456 
exclusion was set to 30s. The mass spectrometry proteomics data and search results 457 
have been deposited to the ProteomeXchange Consortium via the PRIDE partner 458 
repository (Perez-Riverol et al., 2019) with the dataset identifier PXD022903. 459 
 460 
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BioID experiments 461 
NB4 stable cell lines were grown in RPMI supplemented with tetracycline free FCS. 462 
Cells were seeded in exponential growth phase in media supplemented with 1mM 463 
biotin and 1µg/ml doxycycline. Cells were harvested after 24h by centrifugation and 464 
washed twice with ice cold PBS. Cell pellets were resuspended in modified RIPA 465 
buffer (lysis buffer: 50 mM tris-HCl (pH 7.2), 150 mM, NaCl, 1% NP-40, 1 mM EDTA, 466 
1 mM EGTA, 0.1% SDS, 1% sodium deoxycholate, freshly added protease inhibitors) 467 
and incubated on ice for 20 min. Samples were sonicated with a probe sonicator for 5 468 
pulses and centrifuged for 20 min at 4°C, 20 000g. For each pulldown (1x 15 cm 469 
dish), 80µl neutravidin-agarose bead slurry (Thermo Fisher Scientific) was used. 470 
Beads were washed twice in lysis buffer and added to the protein extracts. The 471 
samples incubated rotating at 4°C for 2.5 h. Beads were washed 3x with lysis buffer, 472 
1x with 1M KCl, 1x 2M Urea in 50mM Tris pH8 and 3x with 50mM Tris pH8. Washing 473 
buffers were kept on ice and each washing step was performed with 1ml, inverting 474 
the tube 5 times and then centrifuging for 1 min at 2000g to pellet the beads. Washed 475 
beads were resuspended in 80µl urea/trypsin buffer (2M urea, 50mM Tris pH7.5, 476 
1mM DTT, 5µg/ml trypsin) and incubated 1h at RT on a tubeshaker at 1000rpm. The 477 
supernatant was transferred into a fresh tube, the beads washed twice with 60µl 2M 478 
urea/50mM Tris pH7.5 and the supernatant combined with the supernatant from the 479 
previous step. Residual beads were removed by an additional centrifugation (1 min, 480 
5000g) and sample transfer step. Eluted proteins were reduced with 4mM DTT for 30 481 
min on a tubeshaker (RT, 1000 rpm). Proteins were alkylated with 10mM IAA in the 482 
dark for 45 min (RT, 1000 rpm) and digested over night with 0.5µg trypsin at RT on a 483 
thermoshaker at 700 rpm. For an AspN digest, 0.5 µg of trypsin and 0.5 µg AspN 484 
were added to the sample. Following overnight digestion, samples were acidified by 485 
adding TFA and desalted with stage tips.  486 
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Targeted MS analysis of R142 methylation  487 
Synthetic heavy peptide standards with the sequence DGRLEPLEYER and 488 
DGR[me]LEPLEYER were custom synthesized by JPT (spiketides L, labeled at the 489 
C-terminus with heavy arginine (Arg10)). CEBPA BioID pulldowns were digested with 490 
AspN and trypsin and desalted as described. Samples were resuspended in MS 491 
sample buffer containing 100 fmol/µl of synthetic heavy peptides. Parallel reaction 492 
monitoring (PRM) measurements were acquired on a Q exactive HF-X mass 493 
spectrometer coupled to an Easy-nLCTM 1200 HPLC system. Peptides were 494 
separated on a 60 min gradient ramping from 2% to 76% acetonitrile. Data 495 
acquisition mode cycled between a Top1 MS/data dependent MS2 and data 496 
independent measurement of an inclusion list that included the m/z of the synthetic 497 
heavy peptides as well as their light counterparts coming from the sample. 498 
Resolution of MS2 for data independent acquisition was 60 000 with an AGC target 499 
of 1e6, 200 ms maximum IT, 0.7 m/z isolation window and NCE of 27. PRM data was 500 
analyzed with Skyline (Pino et al., 2020). Identity of peptides was verified by 501 
comparison with the elution profile and fragmentation spectrum of heavy peptide 502 
standards.  503 
 504 
Mass spec raw data processing with MaxQuant 505 
Mass spectrometry raw files were processed with MaxQuant (version 1.5.2.8) (Cox 506 
and Mann, 2008) searching against a human protein database containing isoforms 507 
downloaded from uniprot (June 2017) and a database including common 508 
contaminants. Fixed modifications were set to carbamidomethylation of cysteines 509 
and variable modifications were set to methionine oxidation and N-terminal 510 
acetylation. For BioID experiments, lysine biotinylation was added as an additional 511 
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variable modification. Depending on digestion mode (trypsin or LysC only), enzyme 512 
specificity was selected with a maximum of 2 missed cleavages per peptide. The 513 
initial allowed mass deviation of the precursor ion was up to 6 ppm and 20 ppm for 514 
fragments. False-discovery rate was set to 1% on protein and peptide level. For 515 
SILAC measurements, the requantify option was enabled and minimum ratio count 516 
was set to 2. For LFQ analysis, the match between run and fast LFQ option was 517 
used with default settings.  518 
Data analysis of mass spec data 519 
Statistical analysis of the dataset was performed using R-statistical software package 520 
(version 3.4.1). The protein groups output file from MaxQuant was filtered for 521 
contaminants, reverse hits and proteins only identified by site. Minimum peptide 522 
count for SILAC and LFQ data was at least 2 peptides per protein group. For LFQ 523 
datasets, proteins were filtered by detection in at least 3 replicates of the same 524 
sample and missing values were imputed from a distribution at the detection limit of 525 
the mass spectrometer. For this purpose a normal distribution was created for each 526 
run, with a mean 1.8 standard deviations away from the observed mean and a 527 
standard deviation of 0.3 x the observed standard deviation. LFQ data was analysed 528 
with a two sample moderated t-test (Limma package) and p-values were corrected 529 
for multiple testing with Benjamini-Hochberg procedure. The significance cutoff of 530 
CEBPA interactors was enrichment against both controls (BirA* only and cells not 531 
treated with doxycycline) with an FDR < 0.05. For isoform and tR>L mutant specific 532 
interactors, threshold was enrichment against both controls with an FDR < 0.05 and 533 
FDR < 0.1 in the pairwise comparison of isoforms and mutants. Interactors 534 
overlapping between PRISMA and BioID or BioID and literature (STRING and 535 
BioGrid database, Grebien et al., Giambruno et al.) were visualized with the STRING 536 
app built into cytoscape (v3.71) (Shannon et al., 2003). Known interaction 537 
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(experimentally validated or deposited in databases with a score > 0.5) were 538 
visualized as edges. Interactors not connected by any edges were removed from 539 
figure 2C (12 proteins). GO term analysis of interactors was performed with DAVID 540 
functional annotation tool (version 6.8) (Huang et al., 2009). PRISMA data was 541 
analysed with a two sample moderated t-test (Limma package), creating a specific 542 
control group for each peptide that contained all other peptides excluding peptides 543 
with a sequence overlap ≥ 50%. P-values were corrected for multiple testing with 544 
Benjamini-Hochberg procedure, significance cut off was < 0.1 FDR. To obtain 545 
binding profiles of interactors, LFQ intensities of significant proteins were normalized 546 
between 0 and 1 across all PRISMA peptides.  547 
Microarray 548 
Cells were harvested at exponential growth phase and seeded at 0.5 x 106 cells/ml in 549 
RPMI supplemented with or without 1µg/µl doxycycline as independent biological 550 
triplicates. After 24h cells were harvested via centrifugation (1200 g, 5 min, 4°C) and 551 
washed once with 1x ice cold PBS. Total RNA was extracted with the RNeasy Mini 552 
Kit (Qiagen) following manufacturer’s instructions. DNA was removed with the DNase 553 
Max Kit (Qiagen) following manufacturer’s instructions. RNA integrity was assessed 554 
using a Fragment Analyzer system and a standard sensitivity RNA kit. All RQN 555 
scores were above 9.1. RNA expression analysis was performed with Affymetrix 556 
Human ClariomS® microarray using the WT Plus Reagent kit (ThermoFisher 557 
Scientific). As starting material, 100ng of total RNA was used and RNA was prepared 558 
for hybridization with the GeneChip® Whole Transcript (WT) PLUS Reagent Kit 559 
(ThermoFisher Scientific) following manufactures instructions. CEL files were 560 
processed using the standard Transcriptome Analysis Console (TAC 4.0) software. 561 
Expression values were automatically normalized and summarized using SST-RMA 562 
method. Only mRNAs with log2 expression above 6 in at least one sample were 563 
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considered for further analysis. Statistical analysis was performed using LIMMA 564 
package of R/Bioconductor and p-values were adjusted using Benjamini-Hochberg’s 565 
FDR. Microarray data have been deposited in the ArrayExpress database at EMBL-566 
EBI (www.ebi.ac.uk/arrayexpress) under accession number E-MTAB-9947. 567 
 568 
GSEA of microarray data 569 
Gene expression changes induced by CEBPA isoforms were calculated by 570 
comparing microarray data from NB4 cells expressing CEBPA (P42 or P30) against 571 
BirA* expressing cells. Averaged log2 fold changes were used as input for the single 572 
sample gene set enrichment analysis (ssGSEA) analysis tool (Barbie et al., 573 
2009) implemented in R (https://github.com/broadinstitute/ssGSEA2.0) using 574 
standard parameters. Data was analyzed employing immunologic and transcription 575 
factor target gene sets from the molecular signature database (Subramanian et al., 576 
2005). The running score displayed in Fig.4 was calculated with Kolmogorov-Smirnov 577 
running sum statistics. 578 
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Figure Legends 819 
Figure 1: PRISMA delineates the linear interactome of CEBPA across 820 
conserved regions and PTM sites. A: Schematic scaled depiction of CEBPA 821 
conserved regions (CRs) and post-translational modification (PTM) sites. Spot 822 
synthesized, immobilized peptides with and without PTMs covering the complete 823 
amino acid sequence of CEBPA were screened for protein interactions with PRISMA. 824 
B: Line plots show liquid-liquid phase separation (LLPS; http://protdyn-fuzpred.org) 825 
and molecular recognition feature prediction (MoRF; 826 
https://morf.msl.ubc.ca/index.xhtml) across the CEBPA sequence. Heatmap shows 827 
the binding profile of all significant proteins (y-axis) across CEBPA PRISMA peptides 828 
ordered from N- to C-terminus (x-axis). Bar plot on top corresponds to the summed 829 
normalized LFQ intensities of all significant proteins in each peptide spot. C: 830 
Extracted CEBPA PRISMA profiles of Mediator and P300 complex (top) and 831 
BAF/SWI-SNF complex (bottom) subunits.  832 
Figure 2: Integration of BioID and PRISMA data revealed a spatial CEBPA 833 
interactome with high interconnectivity. A: BioID proximity labelling data obtained 834 
in living cells was integrated with biochemical data obtained with PRISMA. B: The 835 
CEBPA BioID interactome. Log fold changes (CEBPA/control) of proteins are plotted 836 
against their p-values. C: Integrated protein interaction network of CEBPA. Color of 837 
nodes corresponds to detection in datasets as depicted in the legend. Edges 838 
represent validated protein interactions retrieved from the STRING database. 839 
Interactors not connected by any edges were removed from the plot (12 proteins). 840 
Figure 3: BAF/SWI-SNF complex subunit SMARCE1 preferentially interacts with 841 
R142 methylated CEBPA. A: PRISMA interaction profile of proteins differentially 842 
binding to CEBPA peptides centered at R142. Peptide sequence is shown on top and 843 
methylation status of R142 is shown at the bottom. Stars denote significance (< 0.1 844 
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FDR) in R142 dimethylated peptide B: BioID experiments with wildtype CEBPA and 845 
trR>L CEBPA. Proteins passing the significance threshold in wildtype to mutant 846 
comparison and significant compared to controls are marked in color. Significant 847 
BAF/SWI-SNF subunits are indicated by bold letters. 848 
Figure 4: BioID with CEBPA p42/p30 isoforms disclose isoform-specific 849 
interactors in conjunction with PRISMA profiles. A: BioID interaction proteomics 850 
and microarray RNA expression profiling were performed with CEBPA isoform (p42 851 
or p30) expressing cells. B: PRISMA profiles of interactors showing preference for 852 
p42 (log2(p42/p30) > 1) or p30 (log2(p42/p30) < - 1) in BioID. LFQ intensities of 853 
proteins were summed across PRISMA peptides corresponding to exclusively p42 or 854 
both isoforms. The resulting numbers were divided by the total LFQ intensity of each 855 
protein across all PRISMA peptides. PTM-modified peptides were omitted from the 856 
calculations. C: Relative enrichment of CEBPA interactors against the control, p42 is 857 
plotted against p30. Proteins marked in color passed 0.1 FDR threshold in a direct 858 
comparison. D: Overlap of up- and downregulated genes as detected by microarray 859 
gene expression profiling (comparison to BirA* cells, FDR < 0.05, absolute fold 860 
change(FC) > 1). E: Induced gene expression changes were subjected to ssGSEA 861 
analysis. Normalized enrichment score (NES) and FDR of informative gene sets are 862 
displayed next to running score line plots. The running score was calculated with 863 
Kolmogorov-Smirnov (K-S) running sum statistics. 864 
 865 
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Supplemental Figures Legends 867 
Supplemental Figure 1: Pearson correlation matrix of PRISMA replicates. 868 
Pearson correlation of log2 LFQ values in each PRISMA spot (114 spots). Replicate 869 
1 is plotted against replicate 2. Annotation bars indicates conserved regions of 870 
CEBPA. 871 
Supplemental Figure 2: Parallel reaction monitoring detects CEBPA 872 
methylation at R142.  873 
Parallel reaction monitoring (PRM) of unmodified (top) and methylated (bottom) 874 
peptides spanning R142. A heavy peptide standard isotopically labeled at the C-875 
terminal arginine was used to confirm the identity of the peptide. Left: MS2 spectrum 876 
of heavy peptide standard; right: elution profile of MS2 fragments of light and heavy 877 
peptides. PRM data was analyzed with Skyline. 878 
 879 
Supplemental Figure 3: CEBPA and CEBPB share interactors in homologous 880 
regions. A: Shared homology of conserved regions in CEBPA and CEBPB. B: 881 
Number of high-confidence CEBPA interactors per conserved region in CEBPA as 882 
detected by PRISMA and BioID (black bars). Grey bars represent interactors that 883 
were also identified as interactors in homologues regions in CEBPB (Dittmar et al., 884 
2019). C: Extracted PRISMA binding profiles of Mediator complex subunits binding to 885 
CEBPA and CEBPB (right). Annotation bar on top indicates conserved regions.  886 
Supplemental Figure 4: GO term enrichment of mapped CEBPA interactors. 887 
PRISMA CEBPA interactors confirmed by BioID were subjected to GO term analysis 888 
using the DAVID tool. Informative significant GO terms (p value < 0.05) are 889 
displayed. Grey indicates no significant enrichment. No GO terms were significantly 890 
enriched in CR7 binders.  891 
 892 
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Supplemental Figure 5: CEBPA P30 specific interactors may represent 893 
therapeutic targets in AML. Dependency scores from CRISPR knockout screens in 894 
AML cell lines extracted from the DepMap portal. Scores of P30 specific interactors 895 
are displayed. Known tumor-suppressor P53 and oncogene MYB are plotted on top 896 
as a reference. 897 
 898 
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Figure 1, Ramberger et al.
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log2(p42/p30) < −1 log2(p42/p30) >  1
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